MSN Templated with L-Dopa Amide Derivatives Outperforms the Efficiency of Free-L-Dopa in Reducing Parkinson’s Behavioral Dysfunction in Mice

This novel strategy may represent a promising alternative to conventional treatment, reducing dose frequency and hence minimizing L-dopa side effects. The results herein emphasize the potential of MSN-based drug delivery systems for PD, providing a basis for future translational research of nanotechnology-based formulations for neurodegenerative disorders.